Literature DB >> 17897335

Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis.

Mario Pelaez-Luna1, Naoki Takahashi, Joel G Fletcher, Suresh T Chari.   

Abstract

BACKGROUND: The timeline of progression of pancreatic cancer from resectable to unresectable disease is unknown. New-onset diabetes often occurs in pancreatic cancer. It is unclear if the cancer is resectable at the onset of diabetes. We (a) determined the resectability of pancreatic cancer on abdominal CT scans done prior to clinical diagnosis and (b) correlated resectability with onset of diabetes.
METHODS: All CT scans done at diagnosis or before pancreatic cancer diagnosis were reviewed and pancreatic changes classified as normal, potentially resectable, or unresectable pancreatic cancer. Fasting blood glucose values obtained at and prior to diagnosis were available in 18 patients. The date of onset of diabetes and the interval between onset of diabetes and diagnosis of cancer were noted.
RESULTS: Thirty patients fulfilled inclusion criteria. Prior to diagnosis, 28 patients had 38 CT scans done at a median of 18 months (range 1-41) before cancer diagnosis. At cancer diagnosis, only 7/30 patients could undergo margin-negative surgical resection. CT scans done >/=6 months prior to diagnosis showed either a normal pancreas (N = 20) or a resectable mass (N = 6); none had unresectable cancer. The mean interval between onset of diabetes and diagnosis of pancreatic cancer was 10 months (range 5-29 months). At the onset of diabetes, 3 patients had normal pancreas, 6 had resectable, and 4 had unresectable pancreatic cancer.
CONCLUSIONS: Pancreatic cancer is frequently undetectable or resectable on CT scans done >/=6 months prior to clinical diagnosis. At onset of diabetes, pancreatic cancers are generally resectable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897335     DOI: 10.1111/j.1572-0241.2007.01480.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

1.  Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation.

Authors:  Douglas S Swords; Mary C Mone; Chong Zhang; Angela P Presson; Sean J Mulvihill; Courtney L Scaife
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

2.  Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study.

Authors:  Wataru Gonoi; Takana Yamakawa Hayashi; Hidemi Okuma; Masaaki Akahane; Yousuke Nakai; Suguru Mizuno; Ryosuke Tateishi; Hiroyuki Isayama; Kazuhiko Koike; Kuni Ohtomo
Journal:  Eur Radiol       Date:  2017-06-19       Impact factor: 5.315

3.  Plectin-1 as a novel biomarker for pancreatic cancer.

Authors:  Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly
Journal:  Clin Cancer Res       Date:  2010-11-23       Impact factor: 12.531

Review 4.  [Metabolic disorders as paraneoplastic syndromes].

Authors:  S Krug; P Michl
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

Review 5.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

Review 6.  Pancreatic Cancer and Diabetes Mellitus.

Authors:  Ayush Sharma; Suresh T Chari
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 7.  Early detection of pancreatic cancer.

Authors:  Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-02

8.  Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.

Authors:  Anna Sandström Gerdtsson; Christer Wingren; Helena Persson; Payam Delfani; Malin Nordström; He Ren; Xin Wen; Ulrika Ringdahl; Carl A K Borrebaeck; Jihui Hao
Journal:  Mol Oncol       Date:  2016-07-12       Impact factor: 6.603

9.  Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Am J Gastroenterol       Date:  2009-06-09       Impact factor: 10.864

10.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.